Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CLF Variant #03 | — | R 13 479 | 14d | — | — | ~2 | ~R 22 266 PFS proxy · indirect | 1 |
ECX Variant #01 | — | R 2 632 | 21d | — | 30.6 mo | 6 | R 15 791 PFS proxy | 3 |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | ~3.8 mo | ~13.9 mo | ~4 | ~R 7 181 PFS proxy · indirect | 2 |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 235 | 28d | — | 23.4 mo | 3 | R 3 706 PFS proxy | 2 |
No neoadjuvant therapy Partial | — | — | — | — | ~19.2 mo | — | — | 8 |
5 of 5 regimens shown